Clinical analysis of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma
10.3969/j.issn.1005-1678.2017.10.040
- VernacularTitle:异丙托溴铵联合硫酸特布他林雾化吸入治疗哮喘急性发作的临床分析
- Author:
hong Qiao LIN
1
;
Wan LIN
Author Information
1. 杭州拱墅区祥符街道社区卫生服务中心 内科
- Keywords:
ipratropium bromide;
terbutaline sulfate;
inhalation;
acute attack of asthma
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):100-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma. Methods 100 patients with acute attack of asthma treated from March 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group received terbutaline sulfate inhalation, and the experimental group received ipratropium bromide combined with terbutaline sulfate inhalation treatment. The patients in the experimental group and the control group were treated for 7 days continuously. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group (94.0%) was significantly higher than that in the control group (72.0%),the difference was statistically significant(P<0.05). The improvement time of dyspnea, rale and cough in control group was significantly longer than that in the experimental group, the difference was statistically significant(P<0.05). Conclusion Ipratropium bromide combined with terbutaline sulfate inhalation in the treatment of acute attack of asthma has better clinical efficacy and shorter clinical symptoms.
